GLP-1s Linked to Lower Mortality in Mental Illness
Adults with serious mental illness saw reduced mortality risks when initiating GLP-1 receptor agonists compared to SGLT2 inhibitors.
Updated on Sept. 30, 2026 in Diabetes
Live Poll
Would you discuss new research findings on medication risks with your doctor for your own health?
A study published on August 26, 2026, in JAMA Psychiatry found that GLP-1 receptor agonist use was associated with lower mortality rates than SGLT2 inhibitor treatment in adults with serious mental illness. The research analyzed health records from over 1.5 million propensity-matched individuals.
Why it matters
This research highlights potential cardiovascular and survival benefits for patients managing both type 2 diabetes and serious mental illness. Understanding how these medications compare helps clinicians weigh treatment options for populations often at higher risk for heart-related complications.
In a retrospective study of 1,528,230 propensity score-matched adults, including 390,368 patients with serious mental illness, researchers compared mortality outcomes between GLP-1 receptor agonist and SGLT2 inhibitor users. Participants were followed for a median of approximately 949 days.
The players
JAMA Psychiatry
A peer-reviewed medical journal that publishes research on psychiatry, mental health, and the intersection of mental and physical wellness.
TriNetX Analytics Network
A global health research network that provides access to de-identified electronic health record data for clinical study and analysis.
The details
Researchers utilized electronic health record data from the TriNetX Analytics Network to emulate a target trial, matching participants based on their clinical histories. GLP-1 receptor agonists mimic natural hormones to regulate blood glucose, while SGLT2 inhibitors work by preventing the kidneys from reabsorbing glucose. The combination of these therapies was associated with superior survival outcomes compared to taking an SGLT2 inhibitor alone across 1, 4, and 10-year intervals.
Timeline
August 26, 2026: Findings were published in the journal JAMA Psychiatry.
September 30, 2026: Date of article publication.
Health Landscape
This study expands upon the growing body of research regarding the use of GLP-1 receptor agonists beyond glycemic control. It situates these medications within the broader framework of cardiovascular risk reduction for complex patient groups.
If you are managing both serious mental illness and type 2 diabetes, the cardiovascular health benefits of your current medication regimen are worth discussing with your doctor. These findings demonstrate the importance of coordinated care when selecting treatments that address both metabolic and mental health needs.
The takeaway
This study suggests that GLP-1 receptor agonists may offer survival advantages for adults living with both serious mental illness and metabolic conditions. Discuss your cardiovascular risk profile and medication options with your primary care physician or psychiatrist to determine the best plan for you.
Further reading
For more information on how medical management is evolving, visit our Diabetes section.
Source note: This article includes information reported by Psychiatry Advisor.
Live Poll
Would you discuss new research findings on medication risks with your doctor for your own health?
